Clarity Pharmaceuticals

Clarity’s Mission

At Clarity, our mission is to develop next-generation radiopharmaceutical products that improve treatment outcomes for children and adults with cancer.

Clarity is a clinical stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on our platform SAR Technology. The SAR Technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.

Find out more

Pharmaceutical Development

Clarity’s clinical development pipeline is underpinned by its proprietary SAR Technology platform that enables highly targeted theranostic radiopharmaceuticals for both the diagnosis (using copper-64) and treatment (using copper-67) of serious diseases.

Clarity’s pipeline covers large cancer indications with significant market opportunities and unmet needs, such as prostate cancer and breast cancer, as well as rare and orphan cancer indications, such as neuroblastoma, an aggressive childhood cancer.

Clarity’s lead product SARTATE™, an oncology theranostic (diagnostic and therapy), is in clinical trials for neuroblastoma and neuroendocrine tumours. Clarity’s next product, SAR-bisPSMA for the treatment of prostate cancer, is in clinical development as a stand alone diagnostic as well as a theranostic product. SAR-Bombesin (SAR-BBN), is a pan-cancer theranostic radiopharmaceutical with increased specificity and in-vivo stability. It is being developed for breast, prostate as well as a range of different cancers.

Find out more